Mechanism study of PD-1/PD-L1 in tumor and its value of diagnosis and treatment of thyroid cancer
10.3760/cma.j.issn.1673-422X.2020.01.007
- VernacularTitle:PD-1/PD-L1在肿瘤中的机制研究及其在甲状腺癌中的诊治价值
- Author:
Lizhuo ZHANG
1
;
Yangyang QIAN
;
Guowan ZHENG
;
Minghua GE
Author Information
1. 浙江中医药大学第二临床医学院，杭州 310053；浙江省人民医院头颈甲状腺外科，杭州 310014
- From:
Journal of International Oncology
2020;47(1):39-42
- CountryChina
- Language:Chinese
-
Abstract:
Programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) are involved in the regulation of immune checkpoints and are closely related to the occurrence and development of tumors. In thyroid cancer, an increase in PD-L1 expression and an increase in PD-1 positive T cells may be predictive of higher invasiveness and a greater risk of recurrence. Anti-PD-1/PD-L1 therapy has had significant effects in many tumors, but the efficacy in thyroid cancer is still relatively limited, which also requires finding biomarkers those can better predict the efficacy. Further understanding of the mechanism of PD-1/PD-L1, the current research status in thyroid cancer, and biomarkers related to its efficacy may provide new treatment methods and ideas for patients with thyroid cancer.
